- Developing a mechanistic model of IVT to include nucleation and growth of magnesium pyrophosphate crystals and subsequent agglomeration of crystals and DNA.
Nathan Stover
Engineer
BioCurie
Jim Villa
Global Head, Research Strategy & Operations
Takeda
Zhaoqian Su
AI Scientist
Takeda
Melissa Landon
Head, Commercial & Business Development, AI & Automation
MilliporeSigma
Dr. Melissa (“Mel”) Landon leads Commercial and Business Development for AI and Automation at Millipore Sigma, the Life Science business of Merck KGaA. With 20 years of experience of building cutting edge platforms across pharma and tech, Mel’s current work focuses on scaling intelligent automation and AI solutions that bridge scientific innovation with commercial value. She brings to this role a cross-disciplinary background spanning life sciences, technology partnerships, and enterprise transformation. Prior to joining MilliporeSigma, Melissa served as Chief Strategy Officer at Cyclica, an AI-enabled tech bio company (acquired by Recursion in 2023). Melissa completed her PhD in Bioinformatics at Boston University and performed postdoctoral studies in biochemistry and X-ray crystallography at Brandeis University.
Sagar Jain
Director, Digital AI Strategy SSF
Roche
Steve Gately
Client Director, Healthcare ISV Platforms
NVIDIA
Steve leads NVIDIA’s engagement with strategic ISV platform partners in the healthcare sector, helping them accelerate their go-to-market initiatives. By integrating partners’ specialized tools and data with NVIDIA’s advanced training and inference technologies, Steve and his team develop cohesive strategies that drive success across key AI-powered healthcare use cases.
Reed Few
Director of Data Science & External Innovation
J&J
Reed Few is Director of External Innovation for Data Science and Digital Health at Johnson and Johnson Innovative Medicine, R&D. With a background spanning real-world data, predictive modeling, and precision medicine, Reed is passionate about finding ways to combine data and AI to bring therapies from concept to approval, faster. In her current role, she looks for partnerships that will help to design better, more diverse clinical trials, improve operational efficiencies, and find digital endpoints that better reflect how patients live and feel in the real world. As of late, her focus has been on initiatives applying generative AI and large language models to accelerate document creation across preclinical, CMC, and clinical domains – advancing smarter, faster, and more connected drug development.
Dr. Eliezer Katz
CMO
Eledon Pharmaceuticals
Dr. Katz is an experienced transplant surgeon and a leader in clinical development in the pharmaceutical industry. Currently, Dr. Katz is the chief medical officer of Eledon Pharmaceutical. Before joining Eledon, Dr. Katz was CMO of eGenesis, a company in the xenotransplantation field. Previously, Dr. Katz served as Vice President and clinical development lead at Viela Bio and Horizon Therapeutics, where he was responsible for developing novel medications for autoimmune-related diseases and organ transplantation.
Dr. Katz earned his MD degree from the Hebrew University-Hadassah Medical School in Jerusalem, Israel.
Dr. Katz joined Viela Bio/Horizon following 30 years of combined academic and pharmaceutical career in the areas of organ transplantation, immunology, and immune-induced diseases.
His academic career as a transplant surgeon spanned 20 years, including directorship of two transplantation programs. The director of the abdominal transplantation division at Integris Baptist Medical Center in Oklahoma City, and an associate professor of surgery and the director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA. During his tenure as a transplant surgeon, Dr. Katz implemented techniques for split liver and living donor liver transplantation, was actively involved in policy making related to organ donation and allocation and led efforts to increase organ donation.
After joining the pharmaceutical industry, Dr. Katz served as the vice president at CTI clinical trial and consulting services, as senior director in transplantation at Medicine Development Group, Pfizer Inc., and at Medimmune/AstraZeneca as a senior director at RIA (respiratory, inflammation, and autoimmunity), where he oversaw clinical development in neuro-inflammation, inflammatory bowel disease, and myositis.
Dr. Katz is an author of more than 60 peer-reviewed publications.
Martha Scott Poindexter
CEO
Animal Health Institute
